Indacaterol/glycopyrrolate Significantly Improves Health Status And Dyspnea In Different Subgroups Of Patients With Moderate-To-Severe COPD: Pooled Analysis Of Flight1 And Flight2 Studies

被引：0
|
作者：
Mahler, D. A. [1 ]
Donohue, J. F. [2 ]
Fucile, S. [3 ]
Yadao, A. [3 ]
Maitra, S. [4 ]
Taylor, A. Fowler [3 ]
Fogel, R. [3 ]
Patalano, F. [5 ]
Banerji, D. [3 ]
机构：
[1] Geisel Sch Med Dartmouth, Lebanon, NH USA
[2] Univ N Carolina, Chapel Hill, NC USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[5] Novartis Pharma AG, Basel, Switzerland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5467
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Analysis of Improvement in SGRQ Component Scores With QVA149: Pooled Data From the FLIGHT1 and FLIGHT2 Studies
    Jones, Paul
    Larbig, Michael
    Maitra, Samopriyo
    FowlerTaylor, Angel
    Banerji, Donald
    CHEST, 2015, 148 (04)
  • [32] Indacaterol 75 μg once daily improves health status in patients with moderate-to-severe COPD: responder analysis
    Mahler, Donald A.
    Dunn, Leonard J.
    Gotfried, Mark H.
    Williams, James
    Lawrence, David
    McBryan, Danny
    PHARMACOTHERAPY, 2012, 32 (10): : E242 - E242
  • [33] Qva149 Improves Lung Function To A Greater Extent Than Monocomponents In Patients With Moderate-To-Severe COPD: The Flight1 Study
    Kerwin, E. M.
    FowlerTaylor, A.
    Ayers, T.
    Thach, C.
    Maitra, S.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [34] Safety Of Qva149 Versus Its Monocomponents And Placebo: A Pooled Safety Analysis From Flight1 And Flight2 Studies
    FowlerTaylor, A.
    Ayers, T.
    Thach, C.
    Patalano, F.
    Schubert-Tennigkeit, A. A.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [35] Qva149 Demonstrates Superior Improvements In Health Status, As Measured By Sgrq, Compared With Placebo In Patients With Moderate-To-Severe COPD: The Flight2 Study
    Jones, P. W.
    Ayers, T.
    FowlerTaylor, A.
    Larbig, M.
    Thach, C.
    Maitra, S.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [36] Long-Term Safety And Tolerability Of Indacaterol/glycopyrrolate In Moderate-To-Severe COPD Patients From The Us: A Subgroup Analysis From The Flight3 Study
    Ferguson, G. T.
    Schubert-Tennigkeit, A. A.
    Thach, C.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [37] Improvement In Lung Function With Twice-Daily Indacaterol/glycopyrrolate Versus Once-Daily Indacaterol In Patients With Moderate-To-Severe COPD: Results From The Flight3 Study
    Mahler, D. A.
    Ferguson, G. T.
    Fucile, S.
    Yadao, A.
    Wang, Q.
    Ayers, T.
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [38] Glycopyrronium Improved Health Status, Dyspnea, and Reduced Rescue Medication Use in Patients With Moderate-to-Severe COPD: Pooled Analysis From GEM1 and GEM2 Studies
    Laforce, Craig
    Kerwin, Edward
    Spangenthal, Selwyn
    D'Andrea, Peter
    Henley, Michelle
    Eckert, Joerg H.
    Patalano, Francesco
    CHEST, 2015, 148 (04)
  • [39] QVA149 Demonstrated Significant Improvement in Lung Function Compared With Placebo and Its Monocomponents: Pooled Analysis From the FLIGHT1 and FLIGHT2 Studies
    Kerwin, Edward
    Ayers, Tim
    FowlerTaylor, Angel
    Patalano, Francesco
    Banerji, Donald
    Maitra, Samopriyo
    CHEST, 2015, 148 (04)
  • [40] Efficacy Of Inhaled Glycopyrrolate For Moderate-To-Severe COPD: A Subgroup Analysis By Gender From The Pooled Gem1 And Gem2 Studies
    Mahler, D. A.
    Satti, A.
    Spangenthal, S.
    Yadao, A.
    D'Andrea, P.
    Uddin, A.
    Franke-Bray, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
12345